• LAST PRICE
    2.4500
  • TODAY'S CHANGE (%)
    Trending Up0.2100 (9.3750%)
  • Bid / Lots
    2.1800/ 20
  • Ask / Lots
    2.5500/ 2
  • Open / Previous Close
    2.3100 / 2.2400
  • Day Range
    Low 2.2301
    High 2.4600
  • 52 Week Range
    Low 1.0500
    High 5.8600
  • Volume
    25,157
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.24
TimeVolumeDERM
09:32 ET1502.31
09:44 ET10002.25
09:46 ET9002.28
09:48 ET7002.3
09:50 ET4992.31
10:13 ET10002.2401
10:15 ET14402.35
10:18 ET17012.38
10:20 ET3002.36
10:22 ET2012.38
10:24 ET23362.33
10:26 ET6002.28
10:27 ET2002.31
10:51 ET14002.3187
10:54 ET1002.4
11:16 ET23012.39
11:18 ET8002.3083
11:20 ET9002.33
11:21 ET3002.37
11:23 ET11902.39
11:25 ET8002.36
01:20 ET1002.375
01:51 ET2002.29
01:58 ET2662.255
02:02 ET2002.3
02:03 ET4002.34
02:05 ET4002.34
02:07 ET11462.39
02:18 ET1002.28
02:20 ET4202.335
03:35 ET10002.45
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDERM
Journey Medical Corp
28.7M
-0.9x
---
United StatesCHME
China Medicine Corp
78.0K
0.0x
---
United StatesPXYN
Praxsyn Corp
790.0
0.0x
---
United StatesINBP
Integrated Biopharma Inc
10.5M
3.4x
+3.74%
United StatesQLI
Qilian International Holding Group Ltd
60.3M
67.7x
---
United StatesAQST
Aquestive Therapeutics Inc
46.6M
-0.5x
---
As of 2023-02-05

Company Information

Journey Medical Corporation is a pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes over seven branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products that have been approved by the United States Food and Drug Administration (FDA) for sale include Qbrexza, Accutane, Targadox, Ximino, and Exelderm Cream and Solution. The Company's product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne, and Exelderm Cream and Solution is an antifungal intended for topical use.

Contact Information

Headquarters
9237 E Via De Ventura Blvd. Suite 105, Suite 105SCOTTSDALE, AZ, United States 85258
Phone
480-434-6670
Fax
302-531-3150

Executives

Executive Chairman of the Board
Lindsay Rosenwald
President, Chief Executive Officer, Director
Claude Maraoui
Interim Chief Financial Officer
Joseph Benesch
General Counsel
Ramsey Alloush
Independent Director
Neil Herskowitz

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$28.7M
Revenue (TTM)
$75.2M
Shares Outstanding
11.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.72
Book Value
$2.43
P/E Ratio
-0.9x
Price/Sales (TTM)
0.4
Price/Cash Flow (TTM)
---
Operating Margin
-35.34%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.